CD8A and ovarian cancer: The combined immunotherapeutic potential of the IL-15 superagonist and the tumor selective vvDD enhanced survival of mice in IP models of MC38 colorectal and ID8 ovarian cancers (17), with CD8+ T cells being the key cells mediating vvDD-IL15/Rα antitumor therapeutic efficacy.